AnaMaria LuisaMolinaMD

Genitourinary Oncology as an Assistant Professor of Medicine at Weill Cornell Medical College, Assistant Attending Physician at New York- Presbyterian Hospital

Request Appointment

Overview of Dr. Molina

Dr. Ana Molina is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, and New York-Presbyterian Hospital. She received her medical degree from University of Miami Leonard M. Miller School of Medicine and has been in practice 14 years. Dr. Molina accepts several types of health insurance, listed below. She is one of 376 doctors at New York-Presbyterian Hospital and one of 376 doctors at New York-Presbyterian Hospital who specialize in Oncology. She also speaks multiple languages, including Spanish. She has more than 100 publications and over 500 citings.

Office
520 East 70th Street
Starr Pavilion, 3rd Floor
New York, NY 10021
Book by Phone+1(628) 209-6810

Clinical Expertise

Urologic radiation oncology, Kidney Neoplasms, Prostatic Neoplasms, Urinary Bladder Neoplasms, Testicular neoplasms, Hematologic oncology

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
NYU Grossman School of MedicineResidency, Internal Medicine, 2003 - 2005
University of Miami Leonard M. Miller School of MedicineClass of 2003

Certifications & Licensure

NY State Medical License 2005 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors Start of enrollment: 2009 Jul 01
Completed
Phase 1
Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC) Start of enrollment: 2011 Jul 01
Completed
Phase 2
BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC) Start of enrollment: 2011 Oct 01
Terminated
Phase 1, Phase 2
Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2014 Aug 01
Completed
Phase 2
An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Start of enrollment: 2016 Jan 08
Completed
Phase 4
Join now to see all

Publications & Presentations

PubMed

The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution.
Duy D Nguyen, William F Hooper, Weisi Liu, Timothy R Chu, Heather Geiger
Nature. 2024-11-01
7 citations
Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study o...
Scott T Tagawa, Charlene Thomas, A Oliver Sartor, Michael Sun, Judith Stangl-Kremser
Journal of Clinical Oncology. 2024-03-01
1 citations
A Pilot Study on Hyperthermic Intraperitoneal Chemotherapy after Radical or Partial Cystectomy with Pelvic Lymph Node Dissection for High-risk Muscle-invasive Bladder ...
Leonardo D Borregales, Siv Venkat, Lina Posada Calderon, Patrick Lewicki, Thomas Flynn
European Urology. 2023-12-01

Press Mentions

Survival Improves in mRCC with Surgical MetastasectomyOctober 20th, 2021

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Other Languages

Spanish

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Choice
Great West PPO
Health Net Oregon PPO
MVP Healthcare PPO
ODS Network
Oxford Health Freedom
Oxford Health Liberty
PacificSource Preferred PSN
Providence Health System Personal Option
QualCare HMO
QualCare PPO
Regence Washington - Preferred Provider Network
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment